An internal standard for the quantification of marbofloxacin
Related Products
Unlabeled Version(s)
24174Marbofloxacin
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Marbofloxacin-d8 (hydrochloride)

Item No. 33273

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl-d8)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid, monohydrochloride
Molecular Formula
C17H11D8FN4O4 • HCl
Formula Weight
406.9
Purity
≥99% deuterated forms (d1-d8)
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: solubleMethanol:Water (1:1): soluble
SMILES
CN1C([2H])([2H])C([2H])([2H])N(C2=C(F)C=C3C4=C2OCN(C)N4C=C(C(O)=O)C3=O)C([2H])([2H])C1([2H])[2H].Cl
InChi Code
InChI=1S/C17H19FN4O4.ClH/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25;/h7-8H,3-6,9H2,1-2H3,(H,24,25);1H/i3D2,4D2,5D2,6D2;
InChi Key
OCRYFLKYXNBUEY-JCYLEXHWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $439

    Add

    5 mg

    $2,085

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Marbofloxacin-d8 is intended for use as an internal standard for the quantification of marbofloxacin (Item No. 24174) by GC- or LC-MS. Marbofloxacin is a fluoroquinolone antibiotic that is active against P. multocida in vitro (MIC = 0.016 μg/ml).1 It exhibits broad-spectrum antibacterial activity mediated by the inhibition of DNA gyrase, with MIC values ranging from 0.016 to 0.4 and 0.19 to 1.7 µg/ml against various Gram-negative and Gram-positive bacterial isolates, respectively.2 Intramuscular administration of marbofloxacin (2 mg/kg) after infection prevents the formation of pulmonary lesions in a bovine calf model of M. haemolytica A1 pneumonia.3 Oral administration of marbofloxacin (2 mg/kg per day) also exhibits antileishmanial activity in a canine model of leishmaniasis, decreasing parasitic load by 72%.4 Formulations containing marbofloxacin have been used in the veterinary treatment of bacterial infections.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Ferran, A.A., Toutain, P.L., and Bousquet-Mélou, A. Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection. Vet. Microbiol. 148(2-4), 292-297 (2011).

    2. Spreng, M., Deleforge, J., Thomas, V., et al. Antibacterial activity of marbofloxacin. A new fluoroquinolone for veterinary use against canine and feline isolates. J. Vet. Pharmacol. Ther. 18(4), 284-289 (1995).

    3. Lhermie, G., Ferran, A.A., Assié, S., et al. Impact of timing and dosage of a fluoroquinolone treatment on the microbiological, pathological, and clinical outcomes of calves challenged with Mannheimia haemolytica. Front. Microbiol. 237(7), (2016).

    4. Pineda, C., Aguilera-Tejero, E., Morales, M.C., et al. Treatment of canine leishmaniasis with marbofloxacin in dogs with renal disease. PLoS One 12(10), e0185981 (2017).